Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.47), $0.05 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $13.37 million versus the consensus estimate of $7.86 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.